• Je něco špatně v tomto záznamu ?

Alcohol consumption and liver phenotype of individuals with alpha-1 antitrypsin deficiency

M. Fromme, CV. Schneider, N. Guldiken, S. Amzou, Y. Luo, M. Pons, J. Genesca, M. Miravitlles, KH. Thorhauge, M. Mandorfer, J. Waern, KM. Schneider, J. Sperl, S. Frankova, M. Bartel, H. Zimmer, M. Zorn, A. Krag, A. Turner, C. Trautwein, P. Strnad

. 2024 ; 44 (10) : 2660-2671. [pub] 20240719

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25004052

BACKGROUND AND AIMS: Alpha-1 antitrypsin deficiency is an inherited disorder caused by alpha-1 antitrypsin (AAT) mutations. We analysed the association between alcohol intake and liver-related parameters in individuals with the heterozygous/homozygous Pi*Z AAT variant (Pi*MZ/Pi*ZZ genotype) found in the United Kingdom Biobank and the European Alpha1 liver consortium. METHODS: Reported alcohol consumption was evaluated in two cohorts: (i) the community-based United Kingdom Biobank (17 145 Pi*MZ, 141 Pi*ZZ subjects, and 425 002 non-carriers [Pi*MM]); and (ii) the European Alpha1 liver consortium (561 Pi*ZZ individuals). Cohort (ii) included measurements of carbohydrate-deficient transferrin (CDT). RESULTS: In both cohorts, no/low alcohol intake was reported by >80% of individuals, while harmful consumption was rare (~1%). Among Pi*MM and Pi*MZ individuals from cohort (i), moderate alcohol consumption resulted in a <30% increased rate of elevated transaminases and ~50% increase in elevated gamma-glutamyl transferase values, while harmful alcohol intake led to an at least twofold increase in the abnormal levels. In Pi*ZZ individuals from both cohorts, moderate alcohol consumption had no marked impact on serum transaminase levels. Among Pi*ZZ subjects from cohort (ii) who reported no/low alcohol consumption, those with increased CDT levels more often had signs of advanced liver disease. CONCLUSIONS: Pi*MZ/Pi*ZZ genotype does not seem to markedly aggravate the hepatic toxicity of moderate alcohol consumption. CDT values might be helpful to detect alcohol consumption in those with advanced fibrosis. More data are needed to evaluate the impact of harmful alcohol consumption.

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Instituto de Salud Carlos 3 Madrid Spain

Department of Clinical Research Faculty of Health Sciences University of Southern Denmark Odense Denmark

Department of Gastroenterology and Hepatology Odense University Hospital Odense C Denmark

Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Health Care Provider of the European Reference Network on Rare Liver Disorders Prague Czech Republic

Department of Internal Medicine 1 and Clinical Chemistry Heidelberg University Hospital Heidelberg Germany

Department of Medicine Gastroenterology and Hepatology Unit Sahlgrenska University Hospital Health Care Provider of the European Reference Network on Rare Liver Disorders Gothenburg Sweden

Department of Pneumology Vall d'Hebron University Hospital Vall d'Hebron Research Institute Barcelona Spain

Division of Gastroenterology and Hepatology Department of Internal Medicine 3 Medical University of Vienna Health Care Provider of the European Reference Network on Rare Liver Disorders Vienna Austria

Institute of Applied Health Research University of Birmingham Birmingham UK

Institute of Forensic and Traffic Medicine Heidelberg University Hospital Heidelberg Germany

Liver Unit Hospital Universitari Vall d'Hebron Vall d'Hebron Research Institute Universitat Autonoma de Barcelona Barcelona Spain

Medical Clinic 3 Gastroenterology Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Health Care Provider of the European Reference Network on Rare Liver Disorders Aachen Germany

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004052
003      
CZ-PrNML
005      
20250402152510.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/liv.16044 $2 doi
035    __
$a (PubMed)39031304
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fromme, Malin $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany $1 https://orcid.org/0000000303825705
245    10
$a Alcohol consumption and liver phenotype of individuals with alpha-1 antitrypsin deficiency / $c M. Fromme, CV. Schneider, N. Guldiken, S. Amzou, Y. Luo, M. Pons, J. Genesca, M. Miravitlles, KH. Thorhauge, M. Mandorfer, J. Waern, KM. Schneider, J. Sperl, S. Frankova, M. Bartel, H. Zimmer, M. Zorn, A. Krag, A. Turner, C. Trautwein, P. Strnad
520    9_
$a BACKGROUND AND AIMS: Alpha-1 antitrypsin deficiency is an inherited disorder caused by alpha-1 antitrypsin (AAT) mutations. We analysed the association between alcohol intake and liver-related parameters in individuals with the heterozygous/homozygous Pi*Z AAT variant (Pi*MZ/Pi*ZZ genotype) found in the United Kingdom Biobank and the European Alpha1 liver consortium. METHODS: Reported alcohol consumption was evaluated in two cohorts: (i) the community-based United Kingdom Biobank (17 145 Pi*MZ, 141 Pi*ZZ subjects, and 425 002 non-carriers [Pi*MM]); and (ii) the European Alpha1 liver consortium (561 Pi*ZZ individuals). Cohort (ii) included measurements of carbohydrate-deficient transferrin (CDT). RESULTS: In both cohorts, no/low alcohol intake was reported by >80% of individuals, while harmful consumption was rare (~1%). Among Pi*MM and Pi*MZ individuals from cohort (i), moderate alcohol consumption resulted in a <30% increased rate of elevated transaminases and ~50% increase in elevated gamma-glutamyl transferase values, while harmful alcohol intake led to an at least twofold increase in the abnormal levels. In Pi*ZZ individuals from both cohorts, moderate alcohol consumption had no marked impact on serum transaminase levels. Among Pi*ZZ subjects from cohort (ii) who reported no/low alcohol consumption, those with increased CDT levels more often had signs of advanced liver disease. CONCLUSIONS: Pi*MZ/Pi*ZZ genotype does not seem to markedly aggravate the hepatic toxicity of moderate alcohol consumption. CDT values might be helpful to detect alcohol consumption in those with advanced fibrosis. More data are needed to evaluate the impact of harmful alcohol consumption.
650    _2
$a lidé $7 D006801
650    12
$a deficit alfa1-antitrypsinu $x genetika $x krev $x diagnóza $x komplikace $7 D019896
650    12
$a pití alkoholu $x škodlivé účinky $7 D000428
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a alfa-1-antitrypsin $x genetika $x krev $7 D000515
650    12
$a transferin $x analýza $x metabolismus $x analogy a deriváty $7 D014168
650    _2
$a lidé středního věku $7 D008875
650    12
$a fenotyp $7 D010641
650    _2
$a dospělí $7 D000328
650    _2
$a játra $x patologie $7 D008099
650    _2
$a gama-glutamyltransferasa $x krev $7 D005723
650    _2
$a genotyp $7 D005838
650    _2
$a kohortové studie $7 D015331
650    _2
$a senioři $7 D000368
651    _2
$a Spojené království $x epidemiologie $7 D006113
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schneider, Carolin V $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany $1 https://orcid.org/0000000267289246
700    1_
$a Guldiken, Nurdan $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany
700    1_
$a Amzou, Samira $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany
700    1_
$a Luo, Yizhao $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany
700    1_
$a Pons, Monica $u Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain $1 https://orcid.org/0000000209853320
700    1_
$a Genesca, Joan $u Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Miravitlles, Marc $u Department of Pneumology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Health Care Provider of the European Reference Network on Rare Lung Disorders (ERN LUNG), Barcelona, Spain
700    1_
$a Thorhauge, Katrine H $u Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark $u Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark $1 https://orcid.org/0000000304110373
700    1_
$a Mandorfer, Mattias $u Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Vienna, Austria $1 https://orcid.org/0000000323300017
700    1_
$a Waern, Johan $u Department of Medicine, Gastroenterology and Hepatology Unit, Sahlgrenska University Hospital, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Gothenburg, Sweden $1 https://orcid.org/0000000244813412
700    1_
$a Schneider, Kai Markus $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Prague, Czech Republic
700    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Prague, Czech Republic $7 xx0329475
700    1_
$a Bartel, Marc $u Institute of Forensic and Traffic Medicine, Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Zimmer, Holger $u Department of Internal Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Zorn, Markus $u Department of Internal Medicine I and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
700    1_
$a Krag, Aleksander $u Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark $u Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
700    1_
$a Turner, Alice $u Institute of Applied Health Research, University of Birmingham, Birmingham, UK
700    1_
$a Trautwein, Christian $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany $1 https://orcid.org/0000000327628247
700    1_
$a Strnad, Pavel $u Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany $1 https://orcid.org/0000000271226379
773    0_
$w MED00007623 $t Liver international $x 1478-3231 $g Roč. 44, č. 10 (2024), s. 2660-2671
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39031304 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250402152506 $b ABA008
999    __
$a ok $b bmc $g 2263663 $s 1240059
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 44 $c 10 $d 2660-2671 $e 20240719 $i 1478-3231 $m Liver international $n Liver Int $x MED00007623
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace